ImmunoPrecise Antibodies Ltd. Quarterly Research And Development Expense in CAD from Q3 2022 to Q3 2024

Taxonomy & unit
ifrs-full: CAD
Summary
ImmunoPrecise Antibodies Ltd. quarterly/annual Research And Development Expense history and growth rate from Q3 2022 to Q3 2024.
  • ImmunoPrecise Antibodies Ltd. Research And Development Expense for the quarter ending October 31, 2024 was CA$1.16M, a 38.3% increase year-over-year.
  • ImmunoPrecise Antibodies Ltd. Research And Development Expense for the twelve months ending October 31, 2024 was CA$5.06M.
  • ImmunoPrecise Antibodies Ltd. annual Research And Development Expense for 2023 was CA$4.04M, a 71.3% decline from 2022.
  • ImmunoPrecise Antibodies Ltd. annual Research And Development Expense for 2022 was CA$14.1M, a 84% increase from 2021.
  • ImmunoPrecise Antibodies Ltd. annual Research And Development Expense for 2021 was CA$7.66M, a 288% increase from 2020.
Research And Development Expense, Trailing 12 Months (CAD)
Research And Development Expense, Quarterly (CAD)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 5.06M 1.16M +320K +38.3% Aug 1, 2024 Oct 31, 2024 6-K 2024-12-10
Q2 2024 4.74M 1.64M +695K +73.4% May 1, 2024 Jul 31, 2024 6-K 2024-09-16
Q1 2024 4.04M 1.26M Feb 1, 2024 Apr 30, 2024 20-F 2024-07-29
Q4 2023 1M -562K -36% Nov 1, 2023 Jan 31, 2024 6-K 2024-03-14
Q3 2023 835K -4.17M -83.3% Aug 1, 2023 Oct 31, 2023 6-K 2024-12-10
Q2 2023 947K May 1, 2023 Jul 31, 2023 6-K 2024-09-16
Q4 2022 1.56M Nov 1, 2022 Jan 31, 2023 6-K 2024-03-14
Q3 2022 5M Aug 1, 2022 Oct 31, 2022 6-K/A 2024-02-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.